Erratum: Mutated telomeres sensitize tumor cells to anticancer drugs independently of telomere shortening and mechanisms of telomere maintenance (Oncogene (2006) 25 (7411-7420) DOI: 10.1038/sj.onc.1209727);Mutated telomeres sensitize tumor cells to anticancer drugs independently of telomere shortening and mechanisms of telomere maintenance

Oncogene

Volumn 25, Issue 56, 2006, Pages 7411-7420

  Cerone, M A ^a,b   Londoo Vallejo J A ^c   Autexier, C ^a,b,d  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c INSTITUT CURIE   (France)

^d MCGILL UNIVERSITY   (Canada)

Author keywords

Anticancer drugs; Mutant template hTR; Telomerase; Telomere uncapping; Telomeres

Indexed keywords

ANTINEOPLASTIC AGENT; DOXORUBICIN; ETOPOSIDE; HOLOENZYME; PACLITAXEL; RIBONUCLEOPROTEIN; RNA; TELOMERASE; TELOMERASE RNA SUBUNIT;

ARTICLE; CANCER CHEMOTHERAPY; CAPPING PHENOMENON; CELL DEATH; CELL PROLIFERATION; CELL VIABILITY; CHROMOSOMAL INSTABILITY; CHROMOSOME REPLICATION; CHROMOSOME SIZE; CONTROLLED STUDY; DRUG SENSITIVITY; DRUG TARGETING; ENZYME INHIBITION; ENZYME REGULATION; HUMAN; HUMAN CELL; MUTATION; PRIORITY JOURNAL; TELOMERE; TUMOR CELL;

EID: 33845231392     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/sj.onc.1210192     Document Type: Erratum

References (46)

1. Brown JM, Attardi LD. (2005). Nat Rev Cancer 5: 231-237.
2. Bryan TM, Englezou A, Dalla Pozza L, Dunham MA, Reddel RR. (1997). Nat Med 3: 1271-1274.
3. Bryan TM, Englezou A, Gupta J, Bacchetti S, Reddel RR. (1995). EMBO J 14: 4240-4248.
4. Castedo M, Perfettini JL, Roumier T, Andreau K, Medema R, Kroemer G. (2004). Oncogene 23: 2825-2837.
5. Cerone MA, Londono-Vallejo JA, Bacchetti S. (2001). Hum Mol Genet 10: 1945-1952.
6. Chen Z, Koeneman KS, Corey DR. (2003). Cancer Res 63: 5917-5925.
7. Christodoulopoulos G, Malapetsa A, Schipper H, Golub E, Radding C, Panasci LC. (1999). Clin Cancer Res 5: 2178-2184.
8. Chung HK, Cheong C, Song J, Lee HW. (2005). Curr Mol Med 5: 233-241.
9. Cimino-Reale G, Pascale E, Battiloro E, Starace G, Verna R, D'Ambrosio E. (2001). Nucleic Acids Res 29: E35.
10. Collins K, Mitchell JR. (2002). Oncogene 21: 564-579.
11. Dunham MA, Neumann AA, Fasching CL, Reddel RR. (2000). Nat Genet 26: 447-450.
12. Feng J, Funk WD, Wang S-S, Weinrich SL, Avilion AA, Chiu C-P et al (1995). Science 269: 1236-1241.
13. Folini M, De Marco C, Orlandi L, Daidone MG, Zaffaroni N. (2000). Eur J Cancer 36: 2137-2145.
14. Guiducci C, Cerone MA, Bacchetti S. (2001). Oncogene 20: 714-725.
15. Hahn WC, Stewart SA, Brooks MW, York SG, Eaton E, Kurachi A et al (1999). Nat Med 5: 1164-1170.
16. Harley CB, Futcher AB, Greider CW. (1990). Nature 345: 458-460.
17. Herbert B-S, Pitts AE, Baker SI, Hamilton SE, Wright WE, Shay JW et al (1999). Proc Natl Acad Sci USA 96: 14276-14281.
18. Jordan MA, Toso RJ, Thrower D, Wilson L. (1993). Proc Natl Acad Sci USA 90: 9552-9556.
19. Karlseder J, Broccoli D, Dai Y, Hardy S, de Lange T. (1999). Science 283: 1321-1325.
20. Kelland LR. (2005). Eur J Cancer 41: 971-979.
21. Kim MM, Rivera MA, Botchkina IL, Shalaby R, Thor AD, Blackburn EH. (2001). Proc Natl Acad Sci USA 98: 7982-7987.
22. Kim NW, Piatyszek MA, Prowse KR, Harley CB, West MD, Ho PLC et al (1994). Science 266: 2011-2015.
23. Kirk KE, Harmon BP, Reichardt IK, Sedat JW, Blackburn EH. (1997). Science 275: 1478-1481.
24. Kondo Y, Kondo S, Tanaka Y, Haqqi T, Barna BP, Cowell JK. (1998). Oncogene 16: 2243-2248.
25. Lee K-H, Rudolph KL, Ju Y-J, Greenberg RA, Cannizzaro L, Chin L et al (2001). Proc Natl Acad Sci USA 98: 3381-3386.
26. Li S, Rosenberg JE, Donjacour AA, Botchkina IL, Hom YK, Cunha GR et al (2004). Cancer Res 64: 4833-4840.
27. Lin J, Smith DL, Blackburn EH. (2004). Mol Cell Biol 15: 1623-1634.
28. Ludwig A, Saretzki G, Holm PS, Tiemann F, Lorenz M, Emrich T et al (2001). Cancer Res 61: 3053-3061.
29. Marusic L, Anton M, Tidy A, Wang P, Villeponteau B, Bacchetti S. (1997). Mol Cell Biol 17: 6394-6401.
30. Masutomi K, Possemato R, Wong JM, Currier JL, Tothova Z, Manola JB et al (2005). Proc Natl Acad Sci USA 102: 8222-8227.
31. Masutomi K, Yu EY, Khurts S, Ben-Porath I, Currier JL, Metz GB et al (2003). Cell 114: 241-253.
32. Misawa M, Tauchi T, Sashida G, Nakajima A, Abe K, Ohyashiki JH et al (2002). Int J Oncol 21: 1087-1092.
33. Nakamura M, Masutomi K, Kyo S, Hashimoto M, Maida Y, Kanaya T et al (2005). Hum Gene Ther 16: 859-868.
34. Park KH, Rha SY, Kim CH, Kim TS, Yoo NC, Kim JH et al (1998). Int J Oncol 13: 489-495.
35. Sharma GG, Gupta A, Wang H, Scherthan H, Dhar S, Gandhi V et al (2003). Oncogene 22: 131-146.
36. Shay JW, Bacchetti S. (1997). Eur J Cancer 33: 787-791.
37. Shin KH, Kang MK, Dicterow E, Kameta A, Baluda MA, Park NH. (2004). Clin Cancer Res 10: 2551-2560.
38. Smith CD, Blackburn EH. (1999). J Cell Biol 145: 203-214.
39. Stewart SA, Ben-Porath I, Carey VJ, O'Connor BF, Hahn WC, Weinberg RA. (2003). Nat Genet 33: 492-496.
40. Takai H, Smogorzewska A, de Lange T. (2003). Curr Biol 13: 1549-1556.
41. Tentori L, Portarena I, Barbarino M, Balduzzi A, Levati L, Vergati M et al (2003). Mol Pharm 63: 192-202.
42. Ward RJ, Autexier C. (2005). Mol Pharm 68: 779-786.
43. Wen J, Cong YS, Bacchetti S. (1998). Hum Mol Genet 7: 1137-1141.
44. Xu L, Blackburn EH. (2004). J Cell Biol 167: 819-830.
45. Yu G-L, Bradley JD, Attardi LD, Blackburn EH. (1990). Nature 344: 126-132.
46. Zhang X, Mar V, Zhou W, Harrington L, Robinson MO. (1999). Genes Dev 13: 2388-2399.